INSTITUTIONAL BIOSAFETY COMMITTEE REVIEW

MEETING MINUTES

Meeting Date:	**Tuesday, April 28, 2026**
Time:	10:00 am Eastern Time
Location:	Zoom Teleconference
Institution:	Northside Hospital, Atlanta, GA
Principal Investigator:	**Scott R. Solomon, MD**
Protocol:	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company, **CA0881000**
NCT Number:	NCT06297226
Meeting Type:	Continuing Review of Protocol and Site
Title:	A Phase 2, Open-Label, Multicenter Study of Arlocabtagene Autoleucel (BMS-986393), a GPRC5D-directed CAR T Cell Therapy in Adult Participants with Relapsed or Refractory Multiple Myeloma (QUINTESSENTIAL)

1. Call to order:

The Meeting was called to order at 10:02 am Eastern Time.

2. Introductions and orientation:

Introductions were made and the Chair oriented members to the meeting procedures.

3. Declaration of quorum:

Five voting members were present, including two local members unaffiliated with the institution. Also present were two Institutional Representatives and IBC Services staff. The Chair declared that a quorum was present.

4. Conflict of Interest:

The Chair requested that voting members report any conflict of interest regarding this meeting. No conflicts of interest were reported.

5. Public posting:

An Institutional Representative confirmed that notice of the meeting was publicly posted. No public comments were received by the site or the Committee regarding this review.

6. Approval of previous meeting minutes:

Minutes Approved - YES: 5 NO: 0 ABSTAIN: 0

7. Review of proposed research:

The Chair provided an overview of the protocol and status of the study.

The Chair noted changes since the last review.

8. Determination for biosafety level and period of IBC oversight:

The Committee previously determined that **BSL-2 containment facilities and practices** are required for CC-95266, since it consists of primary human cells modified using a recombinant lentiviral vector. The Committee reaffirmed this determination.

The Committee previously determined that IBC oversight will continue for **3 months after the last subject's last dose of CC-95266 locally**, provided all other criteria for study closure are met. The Committee reaffirmed this determination.

9. Vote on the Protocol:

The Committee voted for the following determination on the Protocol:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

10. Review of proposed facilities and practices:

The Chair provided an overview of the arrangement for the facilities and practices.

Points of Discussion:

1. An Institutional Representative confirmed that biohazardous waste is temporarily stored underneath a countertop in the HSC Laboratory and then stored in the Biohazard Waste Storage room.
2. An Institutional Representative confirmed that a revised Site Map with an annotation where the temporary biohazardous waste storage bins are stored underneath the counter in the HSC Laboratory was recently submitted to IBC Services.
3. An Institutional Representative confirmed this study agent and other similar study agents, except for one, are prepared in the room near the dosing rooms. The Committee determined that the Biosafety SOPs are acceptable as written.

11. Site requirements:

The Chair reviewed training and communication requirements for maintaining IBC approval with the Institutional Representatives.

12. Vote on the Site:

The Committee voted for the following determination on the Site:

X	APPROVED
	CONDITIONALLY APPROVED
	TABLED
	DISAPPROVED

DETERMINATION VOTE - YES: 5 NO: 0 ABSTAIN: 0

13. Advice to the Institution: None.

14. Meeting adjourned: The meeting was adjourned at 10:15 am Eastern Time.

15. Post-meeting notes: None.

Documents reviewed:
Agenda
Protocol, Amendment 03, dated 09-04-2025
Investigator's Brochure, Version 05, dated 10-01-2025
Global Product Administration Manual, Version 1.0, dated 10-31-2025
Research Modification Evaluation, Protocol, Amendment 03
Research Modification Evaluation, Investigator's Brochure, Addendum 01 to Version 04
Research Modification Evaluation, Investigator's Brochure, Version 05
Research Modification Evaluation, Global Product Administration Manual, Version 1.0
Biological Risk Assessment and Summary, updated 12-02-2025
Site Map, BMT Unit, 4th Floor, dated 01-29-2024
Site Map, HSC Laboratory, dated 01-29-2024
Site Inspection Checklist, GMHC, expires 01-29-2028, updated 04-17-2026
Site Inspection Checklist, Autoclave Addendum, expires 04-20-2028
Photos, HSC Lab, BMT Unit, dated 04-23-2026
Biohazard Sign, Genetically Modified Human Cells, dated 04-20-2026
Biological Safety Cabinet Certifications, HSC Lab, expire 06-2026
SOP, Biosafety for Genetically Modified Human Cells, dated 04-20-2026
SOP Addendum, Biosafety for Autologous Cells, dated 02-13-2026
Training, Shipping Certification, expires 04-2026, 01-2028
CRRF, dated 01-05-2026
Prior Meeting Minutes, Continuing, dated 04-23-2025